183 related articles for article (PubMed ID: 21792009)
1. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.
Wang X; Yang Y; Xu C; Xiao L; Shen H; Zhang X; Li T; Li X
Int J Gynecol Cancer; 2011 Aug; 21(6):996-1003. PubMed ID: 21792009
[TBL] [Abstract][Full Text] [Related]
2. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
Yanokura M; Banno K; Kawaguchi M; Hirao N; Hirasawa A; Susumu N; Tsukazaki K; Aoki D
Oncol Rep; 2007 Jan; 17(1):41-8. PubMed ID: 17143476
[TBL] [Abstract][Full Text] [Related]
3. RNA interference targeting CHFR enhances taxol chemosensitivity in endometrial cancer cells.
Li X; Wang X; Yang Y; Xu C; Shen H
Oncol Rep; 2012 Jul; 28(1):248-54. PubMed ID: 22469813
[TBL] [Abstract][Full Text] [Related]
4. Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors.
Ogi K; Toyota M; Mita H; Satoh A; Kashima L; Sasaki Y; Suzuki H; Akino K; Nishikawa N; Noguchi M; Shinomura Y; Imai K; Hiratsuka H; Tokino T
Cancer Biol Ther; 2005 Jul; 4(7):773-80. PubMed ID: 16123600
[TBL] [Abstract][Full Text] [Related]
5. Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
Takeshita M; Koga T; Takayama K; Yano T; Maehara Y; Nakanishi Y; Sueishi K
Cancer Biol Ther; 2010 Nov; 10(9):933-41. PubMed ID: 20855974
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer.
Yoshida K; Hamai Y; Suzuki T; Sanada Y; Oue N; Yasui W
Anticancer Res; 2006; 26(1A):49-54. PubMed ID: 16475678
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
Satoh A; Toyota M; Itoh F; Sasaki Y; Suzuki H; Ogi K; Kikuchi T; Mita H; Yamashita T; Kojima T; Kusano M; Fujita M; Hosokawa M; Endo T; Tokino T; Imai K
Cancer Res; 2003 Dec; 63(24):8606-13. PubMed ID: 14695171
[TBL] [Abstract][Full Text] [Related]
8. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
9. Connections between CHFR, the cell cycle, and chemosensitivity: Are they critical in cancer?
Keller JA; Erson-Bensan AE; Petty EM
Cancer Biol Ther; 2010 Nov; 10(9):942-4. PubMed ID: 21057211
[No Abstract] [Full Text] [Related]
10. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression.
Privette LM; González ME; Ding L; Kleer CG; Petty EM
Cancer Res; 2007 Jul; 67(13):6064-74. PubMed ID: 17596595
[TBL] [Abstract][Full Text] [Related]
12. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
[TBL] [Abstract][Full Text] [Related]
13. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS
Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas.
Soutto M; Peng D; Razvi M; Ruemmele P; Hartmann A; Roessner A; Schneider-Stock R; El-Rifai W
Cancer; 2010 Sep; 116(17):4033-42. PubMed ID: 20564104
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways.
Li Z; Min W; Gou J
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1001-11. PubMed ID: 24036847
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
[TBL] [Abstract][Full Text] [Related]
17. The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.
Zhang X; Feng Y; Wang XY; Zhang YN; Yuan CN; Zhang SF; Shen YM; Fu YF; Zhou CY; Li X; Cheng XD; Lu WG; Xie X
Cell Death Dis; 2018 Jan; 9(2):93. PubMed ID: 29367628
[TBL] [Abstract][Full Text] [Related]
18. CHFR promoter hypermethylation and reduced CHFR mRNA expression in ovarian cancer.
Gao Y; Lou G; Zhang GM; Sun XW; Ma YY; Yang YM; Liu G
Int J Biol Markers; 2009; 24(2):83-9. PubMed ID: 19634111
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia.
Honda T; Tamura G; Waki T; Kawata S; Nishizuka S; Motoyama T
Br J Cancer; 2004 May; 90(10):2013-6. PubMed ID: 15138487
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
